SCHEMBL4716256

SCHEMBL4716256

COc1ccc(-c2cnnc(Nc3cccc4cnccc34)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
LMNA P02545 3/20 0.51
MAPT P10636 3/20 0.51
TRPV1 Q8NER1 7/20 0.47
ROCK2 O75116 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 2/20 0.42
NSD2 O96028 1/20 0.42
RAB9A P51151 1/20 0.42
PTGDR Q13258 1/20 0.41
ACP1 P24666 2/20 0.41
CNR2 P34972 1/20 0.40
CCR4 P51679 1/20 0.40
THRB P10828 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716143 0.84 TRPV1 (0.47) TRPV1CCR4
SCHEMBL4715596 0.82 TRPV1 (0.58) ALDH1A1MAPTTRPV1ROCK2SMN1; SMN2
SCHEMBL4715609 0.79 ACP1 (0.52) ALDH1A1LMNAMAPTTRPV1ROCK2
SCHEMBL4715615 0.77 GABRG2 (0.54) ROCK2CYP1A2CYP3A4CYP2C9
SCHEMBL4719442 0.77 ALDH1A1 (0.44) ALDH1A1LMNAMAPTTRPV1ROCK2
SCHEMBL4825028 0.72 ALDH1A1 (0.47) ALDH1A1MAPTTRPV1SMN1; SMN2KDM4E
SCHEMBL4719798 0.72 TRPV1 (0.54) TRPV1ROCK2CNR2
SCHEMBL4717896 0.72 TRPV1 (0.51) TRPV1CCR4CYP3A4CYP2D6
SCHEMBL4718648 0.72 TRPV1 (0.48) ALDH1A1MAPTTRPV1ROCK2SMN1; SMN2
SCHEMBL4718950 0.72 CCR4 (0.44) ALDH1A1LMNAMAPTTRPV1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 ALDH1A1 2473/4885LMNA 4537/4885MAPT 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.